Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Dementia | Study protocol

The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce—randomised controlled trial

Authors: M. Poppe, L. Duffy, N. L. Marchant, J. A. Barber, R. Hunter, N. Bass, A. M. Minihane, K. Walters, P. Higgs, P. Rapaport, I. A. Lang, S. Morgan-Trimmer, J. Huntley, Z. Walker, H. Brodaty, H. C. Kales, K. Ritchie, A. Burton, J. Wenborn, A. Betz, C. Cooper

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Large-scale trials of multidomain interventions show that modifying lifestyle and psychological risk factors can slow cognitive decline. We aim to determine if a lower intensity, personally tailored secondary dementia prevention programme for older people with subjective or mild objective memory decline, informed by behaviour change theory, reduces cognitive decline over 2 years.

Methods

A multi-site, single-blind randomised controlled trial recruiting 704 older adults at high dementia risk due to mild cognitive impairment (MCI) or subjective cognitive decline (SCD). Participants are randomised using 1:1 allocation ratio to the APPLE Tree intervention versus control arm (dementia prevention information), stratified by site. The intervention explores and implements strategies to promote healthy lifestyle, increase pleasurable activities and social connections and improve long-term condition self-management. Two facilitators trained and supervised by a clinical psychologist deliver ten, 1-h group video call sessions over 6 months (approximately every fortnight), video-call ‘tea breaks’ (less structured, facilitated social sessions) in intervening weeks and individual goal-setting phone calls every 2 weeks. From 6 to 12 months, participants meet monthly for ‘tea breaks’, with those not attending receiving monthly goal-setting phone calls. Participants receive a food delivery, pedometer and website access to cognitive training and information about lifestyle modification. Follow-ups for all outcome measures are at 12 and 24 months. The primary outcome is cognition (Neuropsychological Test Battery (NTB) score) at 24 months. Secondary outcomes are quality of life, cost per quality-adjusted life year (QALY) and wellbeing and lifestyle factors the intervention targets (diet, vascular risk, body weight, activity, sleep, anxiety, depression, social networks and loneliness, alcohol intake and smoking). Participants from purposively selected sites participate in qualitative process evaluation interviews, which will be analysed using thematic analytic methods.

Discussion

If effective, the intervention design, involving remote delivery and non-clinical facilitators, would facilitate intervention roll-out to older people with memory concerns.

Trial registration

ISRCTN17325135. Registration date 27 November 2019
Appendix
Available only for authorised users
Literature
2.
go back to reference Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.CrossRef Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.CrossRef
5.
go back to reference Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–89. https://doi.org/10.1016/S1474-4422(17)30040-6.CrossRefPubMed Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–89. https://​doi.​org/​10.​1016/​S1474-4422(17)30040-6.CrossRefPubMed
7.
go back to reference Heffernan M, Andrews G, Fiatarone Singh MA, Valenzuela M, Anstey KJ, Maeder A, et al. Maintain your brain: protocol of a 3-year randomized controlled trial of a personalized multi-modal digital health intervention to prevent cognitive decline among community dwelling 55 to 77 year olds. J Alzheimers Dis. 2019;70(s1):S221–37. https://doi.org/10.3233/JAD-180572.CrossRefPubMedPubMedCentral Heffernan M, Andrews G, Fiatarone Singh MA, Valenzuela M, Anstey KJ, Maeder A, et al. Maintain your brain: protocol of a 3-year randomized controlled trial of a personalized multi-modal digital health intervention to prevent cognitive decline among community dwelling 55 to 77 year olds. J Alzheimers Dis. 2019;70(s1):S221–37. https://​doi.​org/​10.​3233/​JAD-180572.CrossRefPubMedPubMedCentral
8.
go back to reference Cooper C, Aguirre E, Barber JA, Bass N, Brodaty H, Burton A, et al. APPLE-Tree (Active Prevention in People at risk of dementia: Lifestyle, bEhaviour change and Technology to REducE cognitive and functional decline) programme: Protocol. Int J Geriatr Psychiatry. 2020;35(8):811–9. https://doi.org/10.1002/gps.5249 Epub 2019 Dec 23. PMID: 31833588.CrossRefPubMed Cooper C, Aguirre E, Barber JA, Bass N, Brodaty H, Burton A, et al. APPLE-Tree (Active Prevention in People at risk of dementia: Lifestyle, bEhaviour change and Technology to REducE cognitive and functional decline) programme: Protocol. Int J Geriatr Psychiatry. 2020;35(8):811–9. https://​doi.​org/​10.​1002/​gps.​5249 Epub 2019 Dec 23. PMID: 31833588.CrossRefPubMed
9.
go back to reference Poppe M, Mansour H, Rapaport P, Palomo M, Burton A, Morgan-Trimmer S, et al. “Falling through the cracks”; stakeholders' views around the concept and diagnosis of mild cognitive impairment and their understanding of dementia prevention. Int J Geriatr Psychiatry. 2020;35(11):1349–57. https://doi.org/10.1002/gps.5373 Epub 2020 Jul 21. PMID: 32608171.CrossRefPubMed Poppe M, Mansour H, Rapaport P, Palomo M, Burton A, Morgan-Trimmer S, et al. “Falling through the cracks”; stakeholders' views around the concept and diagnosis of mild cognitive impairment and their understanding of dementia prevention. Int J Geriatr Psychiatry. 2020;35(11):1349–57. https://​doi.​org/​10.​1002/​gps.​5373 Epub 2020 Jul 21. PMID: 32608171.CrossRefPubMed
10.
go back to reference Cooper C, Mansour H, Carter C, Rapaport P, Morgan-Trimmer S, Marchant NL, et al. Social connectedness and dementia prevention: pilot of the APPLE-Tree video-call intervention during the Covid-19 pandemic. Dementia (London). 2021:14713012211014382. https://doi.org/10.1177/14713012211014382 Epub ahead of print. PMID: 33913362. Cooper C, Mansour H, Carter C, Rapaport P, Morgan-Trimmer S, Marchant NL, et al. Social connectedness and dementia prevention: pilot of the APPLE-Tree video-call intervention during the Covid-19 pandemic. Dementia (London). 2021:14713012211014382. https://​doi.​org/​10.​1177/​1471301221101438​2 Epub ahead of print. PMID: 33913362.
12.
go back to reference Cooper C, Lodwick R, Walters K, et al. Observational cohort study: Deprivation and access to anti-dementia drugs in the UK. Age Ageing. 2015;45:148–54.CrossRef Cooper C, Lodwick R, Walters K, et al. Observational cohort study: Deprivation and access to anti-dementia drugs in the UK. Age Ageing. 2015;45:148–54.CrossRef
14.
go back to reference Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. The Lancet Neurology. 2020;19(3):271–8.CrossRef Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. The Lancet Neurology. 2020;19(3):271–8.CrossRef
15.
go back to reference Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014;10(6):844–52.CrossRef Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014;10(6):844–52.CrossRef
16.
go back to reference Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–9.CrossRef Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–9.CrossRef
18.
go back to reference Corbett A, Owen A, Hampshire A, Grahn J, Stenton R, Dajani S, et al. The effect of an online cognitive training package in healthy older adults: an online randomized controlled trial. J Am Med Dir Assoc. 2015;16(11):990–7.CrossRef Corbett A, Owen A, Hampshire A, Grahn J, Stenton R, Dajani S, et al. The effect of an online cognitive training package in healthy older adults: an online randomized controlled trial. J Am Med Dir Assoc. 2015;16(11):990–7.CrossRef
19.
go back to reference Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. ArchNeurol. 2007;64(9):1323–9. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. ArchNeurol. 2007;64(9):1323–9.
21.
go back to reference Beecham J, Knapp M. Costing psychiatric intervention. In: Thornicrost C, Brewin C, Wing J, editors. Measuring mental health needs. London: Gaskell; 2001. Beecham J, Knapp M. Costing psychiatric intervention. In: Thornicrost C, Brewin C, Wing J, editors. Measuring mental health needs. London: Gaskell; 2001.
22.
go back to reference Wolfs CA, Dirksen CD, Kessels A, Willems DC, Verhey FR, Severens JL. Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments. Health Qual Life Outcomes. 2007;5:33.CrossRef Wolfs CA, Dirksen CD, Kessels A, Willems DC, Verhey FR, Severens JL. Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments. Health Qual Life Outcomes. 2007;5:33.CrossRef
23.
go back to reference Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52(2):69–77.CrossRef Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52(2):69–77.CrossRef
24.
go back to reference Martinez-Gonzalez MA, Garcia-Arellano A, Toledo E, et al. A 14-item Mediterranean diet assessment tool and obesity indexes among high risk subjects: the PREDIMED trial. PLoS One. 2012;7(8). Martinez-Gonzalez MA, Garcia-Arellano A, Toledo E, et al. A 14-item Mediterranean diet assessment tool and obesity indexes among high risk subjects: the PREDIMED trial. PLoS One. 2012;7(8).
27.
go back to reference Saunders JB, Aasland OG, Babor TF, Delafuente JR, Grant M. Development of the Alcohol-Use Disorders Identification Test (Audit) - WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol-Consumption .2. Addiction. 1993;88(6):791–804.CrossRef Saunders JB, Aasland OG, Babor TF, Delafuente JR, Grant M. Development of the Alcohol-Use Disorders Identification Test (Audit) - WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol-Consumption .2. Addiction. 1993;88(6):791–804.CrossRef
28.
go back to reference Brugha TS, Morgan Z, Bebbington P, et al. Social support networks and type of neurotic symptom among adults in British households. Psychol Med. 2003;33(2):307–18.CrossRef Brugha TS, Morgan Z, Bebbington P, et al. Social support networks and type of neurotic symptom among adults in British households. Psychol Med. 2003;33(2):307–18.CrossRef
29.
go back to reference Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A short scale for measuring loneliness in large surveys: results from two population-based studies. Research on Aging. 2004;26(6):655–72.CrossRef Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A short scale for measuring loneliness in large surveys: results from two population-based studies. Research on Aging. 2004;26(6):655–72.CrossRef
32.
go back to reference Goldberg DP, Williams P. A user’s guide to the General Health Questionnaire. Windsor, UK: NFER-Nelson; 1988. Goldberg DP, Williams P. A user’s guide to the General Health Questionnaire. Windsor, UK: NFER-Nelson; 1988.
33.
go back to reference Brugha T, Bebbington P, Tennant C, Hurry J. The list of threatening experiences - a subset of 12 life evnt categories with considerable long-term contextual threat. Psychol Med. 1985;15(1):189–94.CrossRef Brugha T, Bebbington P, Tennant C, Hurry J. The list of threatening experiences - a subset of 12 life evnt categories with considerable long-term contextual threat. Psychol Med. 1985;15(1):189–94.CrossRef
34.
go back to reference Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015.
35.
go back to reference Topic ICH. E 9 Statistical Principles for Clinical Trials. EMEA Sept. 1998; (https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf). Topic ICH. E 9 Statistical Principles for Clinical Trials. EMEA Sept. 1998; (https://​www.​ema.​europa.​eu/​en/​documents/​scientific-guideline/​ich-e-9-statistical-principles-clinical-trials-step-5_​en.​pdf).
36.
go back to reference Walwyn R, Roberts C. Therapist variation within randomised trials of psychotherapy: implications for precision, internal and external validity. Stat Methods Med Res. 2010;19(3):291–315.CrossRef Walwyn R, Roberts C. Therapist variation within randomised trials of psychotherapy: implications for precision, internal and external validity. Stat Methods Med Res. 2010;19(3):291–315.CrossRef
41.
go back to reference Bazeley P. Integrating analyses in mixed methods research. London: Sage; 2018.CrossRef Bazeley P. Integrating analyses in mixed methods research. London: Sage; 2018.CrossRef
44.
go back to reference Munanga A. Cybercrime: a new and growing problem for older adults. J Gerontol Nurs. 2019;45(2):3–5.CrossRef Munanga A. Cybercrime: a new and growing problem for older adults. J Gerontol Nurs. 2019;45(2):3–5.CrossRef
Metadata
Title
The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce—randomised controlled trial
Authors
M. Poppe
L. Duffy
N. L. Marchant
J. A. Barber
R. Hunter
N. Bass
A. M. Minihane
K. Walters
P. Higgs
P. Rapaport
I. A. Lang
S. Morgan-Trimmer
J. Huntley
Z. Walker
H. Brodaty
H. C. Kales
K. Ritchie
A. Burton
J. Wenborn
A. Betz
C. Cooper
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06557-6

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue